Clinical Trials Logo

Filter by:
NCT ID: NCT04541628 Terminated - Hemophilia A Clinical Trials

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Start date: September 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

SIG-001-121 is a first-in-human (FIH), phase 1/2, multi-centre, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SIG-001 in adults with severe or moderately severe haemophilia A without inhibitors. Up to three dose cohorts (3 patients each) are planned. Cohort expansions (up to 3 additional patients) may be triggered to collect additional information about safety and efficacy.

NCT ID: NCT04537832 Terminated - Dravet Syndrome Clinical Trials

Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies

ENVISION
Start date: January 18, 2021
Phase:
Study type: Observational

This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.

NCT ID: NCT04533737 Terminated - Psoriasis Clinical Trials

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

COBRA
Start date: December 17, 2020
Phase: Phase 4
Study type: Interventional

The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.

NCT ID: NCT04515394 Terminated - Clinical trials for Colorectal Neoplasms

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC) having acquired resistance to anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal epithelial transition (MET) amplification.

NCT ID: NCT04506866 Terminated - Overactive Bladder Clinical Trials

InterStim Micro Post Market Clinical Follow-up Study

ELITE
Start date: August 25, 2020
Phase: N/A
Study type: Interventional

Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.

NCT ID: NCT04506619 Terminated - Clinical trials for Bronchopulmonary Dysplasia

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Start date: September 9, 2020
Phase:
Study type: Observational

The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.

NCT ID: NCT04504032 Terminated - COVID-19 Clinical Trials

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Start date: September 2, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.

NCT ID: NCT04502433 Terminated - Clinical trials for Acute Respiratory Distress Syndrome

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Start date: January 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress syndrome (ARDS).

NCT ID: NCT04501952 Terminated - COVID-19 Clinical Trials

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

Start date: September 18, 2020
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.

NCT ID: NCT04494061 Terminated - Graft Failure Clinical Trials

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Start date: November 16, 2020
Phase:
Study type: Observational

Clinical study designed to collect blood for research purposes in patients after hematopoietic stem cell transplantation (HSCT) or in patients with a medical condition where the blood cells production is impaired. The blood samples will be used to study the role of Interferon gamma (IFNɣ) in graft failure or impairment of hematopoietic stem cell proliferation. The IFNɣ signature will be assessed by measuring primarily IFNɣ and C-X-C Motif Chemokine Ligand 9 (CXCL9).